Alpha 2.0
Login Register
» Authors » Louise Garside

Louise Garside

Explore the profile of Louise Garside including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 22
Followers 0
Related Specialties
Infectious Diseases
Pharmacology
Top 10 Co-Authors
Rodica Van Solingen-Ristea
Bryan Baugh
Jean van Wyk
Parul Patel
Joseph W Polli
Ronald DAmico
Susan L Ford
Herta Crauwels
Eileen Birmingham
Nadine Chamay
Published In
HIV Med
Antimicrob Agents Chemother
J Infect Dis
Open Forum Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials
Elliot E, Polli J, Patel P, Garside L, Grove R, Barnett V, et al.
J Infect Dis . 2024 Jul; 230(1):e34-e42. PMID: 39052748
Background: Cabotegravir plus rilpivirine (CAB + RPV) is a guideline-recommended long-acting (LA) injectable regimen for the maintenance of human immunodeficiency virus-1 (HIV-1) virologic suppression. This post hoc analysis summarizes CAB...
2.
Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration
Teichner P, Chamay N, Elliot E, Pascual-Bernaldez M, Merrill D, Garris C, et al.
Open Forum Infect Dis . 2024 Jun; 11(6):ofae282. PMID: 38882931
Background: Cabotegravir (CAB) + rilpivirine (RPV) dosed monthly or every 2 months is a complete long-acting (LA) regimen for the maintenance of human immunodeficiency virus type 1 virologic suppression. Across...
3.
Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96
Oka S, Holohan V, Shirasaka T, Choi J, Kim Y, Chamay N, et al.
HIV Med . 2023 Dec; 25(3):381-390. PMID: 38147871
Objectives: Cabotegravir + rilpivirine (CAB + RPV) dosed monthly or every 2 months is the first complete long-acting (LA) regimen recommended by treatment guidelines for the maintenance of HIV-1 virological...
4.
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials
Patel P, Ford S, Baker M, Meyer C, Garside L, DAmico R, et al.
HIV Med . 2022 Nov; 24(5):568-579. PMID: 36411596
Background: Limited data exist on pregnant women living with HIV exposed to cabotegravir + rilpivirine (CAB + RPV). Outcomes in pregnant participants exposed to CAB + RPV, and pharmacokinetic washout...
5.
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
Gartland M, Cahn P, DeJesus E, Diaz R, Grossberg R, Kozal M, et al.
Antimicrob Agents Chemother . 2022 May; 66(6):e0175121. PMID: 35502922
In the phase 3 BRIGHTE study in heavily treatment-experienced adults with multidrug-resistant HIV-1, fostemsavir plus optimized background therapy (OBT) resulted in sustained rates of virologic suppression through 96 weeks. HIV-1...